Related Experiment Video
Updated: Mar 7, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.1K
Phospholipase D1 expression analysis in relapsing-remitting multiple sclerosis patients.
Mohammad Mahdi Eftekharian1, Tahereh Azimi2, Soudeh Ghafouri-Fard2
1Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Summary
Phospholipase D1 (PLD1) levels are reduced in multiple sclerosis (MS) patients. PLD1 may serve as a biomarker to evaluate treatment response to interferon-beta (IFNβ) in relapsing-remitting MS (RRMS).
Area of Science:
- Neuroimmunology
- Biochemistry
Background:
- Multiple sclerosis (MS) is a chronic CNS disorder involving immune-mediated myelin destruction.
- Disease-modifying agents like interferon-beta (IFNβ) are used to manage MS progression.
- Phospholipase D1 (PLD1) regulates immune responses and produces phosphatidic acid.
Purpose of the Study:
- To investigate PLD1 transcript and plasma levels in relapsing-remitting MS (RRMS) patients.
- To assess the potential of PLD1 as a biomarker for IFNβ treatment response in RRMS.
Main Methods:
- Quantitative real-time RT-PCR for PLD1 transcript levels.
- Enzyme-linked immunosorbent assay (ELISA) for plasma PLD1 concentrations.
- Comparison between 78 RRMS patients and 78 healthy controls, including subgroups of IFNβ responders and non-responders.
Main Results:
- Significant downregulation of PLD1 transcripts and plasma concentrations in RRMS patients compared to controls.
- PLD1 was significantly upregulated in IFNβ responders versus non-responders.
- Downregulation observed in both male and female MS patients.
Conclusions:
- PLD1 expression in blood and plasma may serve as a potential biomarker for assessing therapeutic response to IFNβ in RRMS.
- Further validation studies are required to confirm these findings.
